Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): a Phase I/II Study

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2011, Vol.17 (2), p.S331-S331
Main Authors: Reshef, R, Luger, S.M, Loren, A.W, Frey, N.V, Goldstein, S.C, Hexner, E.O, Stadtmauer, E.A, Smith, J, Mick, R, Heitjan, D.F, Hoxie, J.A, Emerson, S.G, Vonderheide, R.H, Porter, D.L
Format: Article
Language:English
Subjects:
Hematology, Oncology and Palliative Medicine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2010.12.532